$IMMP Immutep Announces Improving Data from the Phase II TACTI-002 Study $MRK #ASCO2020
https://t.co/plc8aTfV8b
- 1st CR reported in 2nd line HNSCC
- iORR in HNSCC, increasing to 38.9% (previously 33%)
- PFS continues to improve in 1st line NSCLC patients, estimated &gt; 9 months